On October 8, 2026, Sunshine Biopharma Inc. entered into a placement agent agreement with Aegis Capital Corp. to conduct a best efforts public offering of securities. The offering was structured to raise gross proceeds of approximately $6.0 million.
The securities offered consisted of two types of units. The first, a Common Unit, included one share of common stock and two Series D warrants. The second, a Pre-Funded Unit, included one pre-funded warrant and two Series D warrants. The purchase price for each Common Unit was $0.55, while each Pre-Funded Unit was priced at $0.54999.
The Pre-Funded Warrants were immediately exercisable and were exercised in full prior to the closing of the transaction. The Series D Warrants are exercisable immediately upon issuance at an initial exercise price of $0.66 per share and will expire five years from the date of issuance. The terms of the Series D Warrants include an adjustment provision that may lower the exercise price if a share combination event occurs and the stock price falls below a specific threshold.
The offering closed on October 9, 2026. Under the agreement, Aegis Capital Corp. received a fee of 7% of the public offering price and a non-accountable expense allowance of 1%. The company expects to use the net proceeds for general corporate purposes and working capital.
The offering was made pursuant to an effective registration statement on Form S-1 (File No. 333-299274) filed with the SEC on October 2, 2026, and declared effective on October 7, 2026. A final prospectus was filed on October 9, 2026.
